Compare LODE & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | OBIO |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 238.3M |
| IPO Year | 2004 | 2020 |
| Metric | LODE | OBIO |
|---|---|---|
| Price | $3.72 | $4.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.00 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 1.7M | 232.6K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | 33.13 |
| EPS | N/A | ★ N/A |
| Revenue | $1,553,796.00 | ★ $33,482,000.00 |
| Revenue This Year | $1,582.85 | N/A |
| Revenue Next Year | $246.20 | $12.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $2.24 | $2.20 |
| 52 Week High | $4.80 | $5.42 |
| Indicator | LODE | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 53.14 |
| Support Level | $3.48 | $3.77 |
| Resistance Level | $3.75 | $4.18 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 0.00 | 81.08 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.